Study title:
Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40−5967), a novel calcium antagonist. Petrie JR, Glen SK, MacMahon M, Crome R, Meredith PA, Elliott HL, Reid JL. Journal of hypertension, Dec 1995, vol. 13, no. 12 Pt 2, p. 1842−6Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40−5967), a novel calcium antagonist. Petrie JR, Glen SK, MacMahon M, Crome R, Meredith PA, Elliott HL, Reid JL. Journal of hypertension, Dec 1995, vol. 13, no. 12 Pt 2, p. 1842−6
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Cardiovascular Diseases [C14]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: DILTIAZEM |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|